Explore
Validate
Learn
Western blotAntibody data
- Antibody Data
- Antigen structure
- References [1]
- Comments [0]
- Validations
- Western blot [1]
- Immunocytochemistry [1]
- Immunohistochemistry [1]
- Other assay [2]
Submit
Validation data
Reference
Comment
Report error
- Product number
- PA5-56183 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- ZNF655 Polyclonal Antibody
- Antibody type
- Polyclonal
- Antigen
- Recombinant full-length protein
- Description
- Immunogen sequence: TDDNDKYDMS FNQNSASGKH EHLNLTEDFQ SSECKESLMD LSHLNKWESI PNTEKSYKCD VCGKIFHQSS ALTRHQRI
- Concentration
- 0.4 mg/mL
Submitted references ZNF655 accelerates progression of pancreatic cancer by promoting the binding of E2F1 and CDK1.
Shao Z, Li C, Wu Q, Zhang X, Dai Y, Li S, Liu X, Zheng X, Zhang J, Fan H
Oncogenesis 2022 Aug 4;11(1):44
Oncogenesis 2022 Aug 4;11(1):44
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Western blot analysis of ZNF655 in Lane 1: Marker (kDa) 230, 130, 95, 72, 56, 36, 28, 17, 11; Lane 2: Human cell line RT-4. Samples were probed using a ZNF655 Polyclonal Antibody (Product # PA5-56183).
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunofluorescent staining of ZNF655 in human cell line A-431 shows positivity in plasma membrane & nucleus but excluded from the nucleoli. Samples were probed using a ZNF655 Polyclonal Antibody (Product # PA5-56183).
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunohistochemical staining of ZNF655 in human esophagus using a ZNF655 Polyclonal Antibody (Product # PA5-56183) shows nuclear and cytoplasmic positivity in squamous epithelial cells.
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Fig. 1 ZNF655 expression is significantly elevated in human pancreatic cancer and possesses clinical value in predicting poor prognosis. A The expression level of ZNF655 in pancreatic cancer was determined by IHC staining and representative images were shown. Magnification is 200 and 400. B The clinical relevance between ZNF655 and Overall survival of pancreatic cancer patients was analyzed by Kaplan-Meier method. * P = 0.032. C The mRNA expression level of ZNF655 in pancreatic cancer cell lines (PANC-1, SW1990 and BXPC-3) and normal pancreatic cell line HPDE6-C7 was identified.
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Knockdown of ZNF655 attenuates tumor formation of pancreatic cancer in vivo. A Post injection of SW1990 cells for 7 days, the tumor volume in mice was measured. B Mice were sacrificed at day 26 post injection, and the tumor weight was measured and photographed. C The expression of ZNF655 and CDK1 in mice tumor tissues was detected by IHC staining. Data was represented as mean +- SD. * P < 0.05, ** P < 0.01, *** P < 0.001.
